title: Recurrent epithelial ovarian cancer and hormone therapy.
abstract: The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase II clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer.
authors.affiliation: Yoshihito Yokoyama, Hideki Mizunuma, Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki 036-8652, Japan.
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Hideki
authors.initials: H
authors.lastname: Mizunuma
keywords: Anastrozole; Fulvestrant; Hormone therapy; Letrozole; Recurrent ovarian cancer; Tamoxifen